Other
Induction Chemotherapy
0
Pipeline Programs↗
13
Active Trials↗
4
Companies Involved↗
Induction Chemotherapy is an early-stage landscape with 0 programs across 4 companies. The most active players are Austrian South Oncology Group, Arog Pharmaceuticals, Inc., WiSP Wissenschaftlicher Service Pharma GmbH.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
61
clinical trials
Completed26 · 43%
Unknown status16 · 26%
Recruiting6 · 10%
Terminated5 · 8%
Active, not recruiting4 · 7%
Not yet recruiting3 · 5%
Other1 · 2%
Clinical Trials
Trial Activity
61 trials
Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC
Active, not recruiting·—·Phase 2·NCT05888402·50 enrolled
Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AML
Active, not recruiting·TThe Children's Hospital of Zhejiang University School of Medicine·Phase 2·NCT07437170·10 enrolled
Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML
Active, not recruiting·—·Phase 3·NCT05177731·188 enrolled
Induction Chemotherapy and Tazemetostat for Locally Advanced SMARCB1-deficient Sinonasal Carcinoma
Not yet recruiting·—·Phase 2·NCT05151588·30 enrolled
Page 1 of 5
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)